These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21358881)

  • 1. A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancer.
    Josephson CB; Al-Azri S; Smyth DJ; Haase D; Johnston BL
    Can J Infect Dis Med Microbiol; 2010; 21(1):e75-8. PubMed ID: 21358881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
    Lam JS; Benson MC; O'Donnell MA; Sawczuk A; Gavazzi A; Wechsler MH; Sawczuk IS
    Urol Oncol; 2003; 21(5):354-60. PubMed ID: 14670544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculous spondylitis following intravesical bcg-instillation in the treatment of transitional cell carcinoma: Case report and systematic review.
    Broekx S; Buelens E
    Clin Neurol Neurosurg; 2020 Jul; 194():105944. PubMed ID: 32480296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pott's disease post intravesical BCG.
    Jain A
    Urol Case Rep; 2023 Jan; 46():102317. PubMed ID: 36687749
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Jain H; Gada K; Zaidi S; Asiago-Reddy E; Eranki A
    Proc (Bayl Univ Med Cent); 2019 Oct; 32(4):577-578. PubMed ID: 31656426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rare case of vertebral osteomyelitis with associated epidural abscess complicating BCG immunotherapy for transitional cell carcinoma of the bladder.
    Berneri M; Murray F; Davel S
    IDCases; 2023; 32():e01773. PubMed ID: 37187939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
    O'Donnell MA; Krohn J; DeWolf WC
    J Urol; 2001 Oct; 166(4):1300-4, discussion 1304-5. PubMed ID: 11547062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and management of superficial bladder cancer.
    Amling CL
    Curr Probl Cancer; 2001; 25(4):219-78. PubMed ID: 11514784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lumbosacral Vertebral Osteomyelitis With Iliopsoas and Epidural Abscess Following Intravesical Bacillus Calmette-Guérin Therapy.
    Abbas AM; Bhandari J; Ngan A; Shahsavarani S; Verma RB
    Cureus; 2023 Oct; 15(10):e47421. PubMed ID: 38021898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
    Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
    J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer.
    Stricker P; Pryor K; Nicholson T; Goldstein D; Golovsky D; Ferguson R; Nash P; Ehsman S; Rumma J; Mammen G; Penny R
    Urology; 1996 Dec; 48(6):957-61; discussion 961-2. PubMed ID: 8973689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
    Prasad SM; Eyre S; Loughlin KR
    Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder.
    Elzein F; Albogami N; Saad M; El Tayeb N; Alghamdi A; Elyamany G
    Clin Med Insights Case Rep; 2016; 9():71-3. PubMed ID: 27559301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical immunotherapy for superficial bladder cancer.
    Said MT; Abomelha MS; Orkubi SA
    Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
    Kaasinen E; Rintala E; Pere AK; Kallio J; Puolakka VM; Liukkonen T; Tuhkanen K
    J Urol; 2000 Jul; 164(1):47-52. PubMed ID: 10840422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.